- Home
- NDSN vs BBIO Comparison
NDSN vs BBIO Comparison
Compare NDSN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDSN
- BBIO
- Stock Information
- Founded
- NDSN 1935
- BBIO 2015
- Country
- NDSN United States
- BBIO United States
- Employees
- NDSN N/A
- BBIO N/A
- Industry
- NDSN Industrial Machinery/Components
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- NDSN Industrials
- BBIO Health Care
- Exchange
- NDSN Nasdaq
- BBIO Nasdaq
- Market Cap
- NDSN 10.1B
- BBIO 9.4B
- IPO Year
- NDSN N/A
- BBIO 2019
- Fundamental
- Price
- NDSN $223.17
- BBIO $51.21
- Analyst Decision
- NDSN Strong Buy
- BBIO Strong Buy
- Analyst Count
- NDSN 6
- BBIO 16
- Target Price
- NDSN $265.33
- BBIO $64.44
- AVG Volume (30 Days)
- NDSN 383.9K
- BBIO 2.2M
- Earning Date
- NDSN 08-20-2025
- BBIO 11-11-2025
- Dividend Yield
- NDSN 1.39%
- BBIO N/A
- EPS Growth
- NDSN N/A
- BBIO N/A
- EPS
- NDSN 7.95
- BBIO N/A
- Revenue
- NDSN $2,784,349,000.00
- BBIO $235,812,000.00
- Revenue This Year
- NDSN $5.77
- BBIO $115.49
- Revenue Next Year
- NDSN $4.99
- BBIO $64.61
- P/E Ratio
- NDSN $28.18
- BBIO N/A
- Revenue Growth
- NDSN 4.49
- BBIO 7.62
- 52 Week Low
- NDSN $165.03
- BBIO $21.72
- 52 Week High
- NDSN $266.86
- BBIO $54.60
- Technical
- Relative Strength Index (RSI)
- NDSN 52.07
- BBIO 52.92
- Support Level
- NDSN $221.09
- BBIO $52.20
- Resistance Level
- NDSN $228.23
- BBIO $54.60
- Average True Range (ATR)
- NDSN 4.06
- BBIO 2.26
- MACD
- NDSN -0.11
- BBIO -0.06
- Stochastic Oscillator
- NDSN 34.71
- BBIO 56.48
About NDSN Nordson Corporation
Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.7 billion in revenue in its fiscal 2024.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.